JAMA to toughen author disclosure rules

Share this article:
The Journal of the American Association (JAMA) will tighten the disclosure demands it places on writers after a series of cases in which authors failed to reveal financial ties with drug makers. JAMA has also issued a correction to a study it published in February that reported pregnant women who stopped taking antidepressant medication were much more likely to suffer a relapse of depression that those who continued taking the medication. The correction said that seven of the study’s 13 authors had relationships with drug makers that weren’t disclosed in the February issue. The undisclosed relationships were reported in The Wall Street Journal. Under the new JAMA guidelines, authors are instructed to more broadly report their connections with drug and medical device makers. Catherine DeAngelis, JAMA’s editor-in-chief told WSJ, “there has to be a certain level of trust” between the publication and authors who publish their research in it. “The day that certain level of trust disappears, I will hang it up.”
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.